Androgen-regulated PMEPA1 gene and polypeptides

• US 7,537,896 B2
• Filed: 06/15/2006
• Issued: 05/26/2009
• Est. Priority Date: 01/28/2000
• Status: Expired due to Fees

• Current Assignee: Henry M Jackson Foundation For The Advancement of Military Medicine Incorporated
• Original Assignee: Henry M Jackson Foundation For The Advancement of Military Medicine Incorporated
• Inventors: Xu, Linda L., Srivastava, Shiv, Moul, Judd W.
• Primary Examiner(s): Yu; Misook
• Assistant Examiner(s): Halvorson; Mark
• Application Number:
  US11/452,925
• Publication Number:
  US 20060269546A1
• Time in Patent Office: 1,076 Days
• Field of Search: None
• US Class Current: 435/6.14
• CPC Class Codes: C07K 14/47 from mammals
• CPC Class Codes: C07K 14/4748 Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE

Abstract

This invention relates to the androgen-regulated gene, PMEPA1, and proteins encoded by this gene, including variants and analogs thereof. Also provided are other androgen-regulated nucleic acids, a polynucleotide array containing these androgen-regulated nucleic acids, and methods of using the polynucleotide array in the diagnosis and prognosis of prostate cancer.

Claims

1. A method of diagnosing prostate cancer, comprising determining the expression of an androgen-regulated gene in a biological sample comprising prostate cells, wherein the androgen-regulated gene is PMEPA1, wherein expression of the PMEPA1 gene is determined by measuring the level of expression of a PMEPA1 nucleotide sequence comprising SEQ ID NO:

2 in the biological sample, and wherein reduced expression of the PMEPA1 gene in the biological sample as compared to a control sample comprising noncancerous prostate cells correlates with an increased probability for the presence of prostate cancer.

2. The method of claim 1, wherein expression of the PMEPA1 gene in the biological sample is reduced at least 1.5 fold as compared to the control sample.

3. The method of claim 1, wherein the level of expression of the PMEPA1 nucleotide sequence is determined after amplifying the PMEPA1 nucleotide sequence in the biological sample.

4. The method of claim 3, wherein the PMEPA1 nucleotide sequence is amplified using a first PCR primer having the nucleotide sequence of SEQ ID NO:

77 and a second PCR primer having the nucleotide sequence of SEQ ID NO;

78.

5. The method of claim 3, wherein the expression of the PMEPA1 nucleotide sequence is detected using a probe having the nucleotide sequence of SEQ ID NO:

79.

6. A method of prognosing the pathologic stage of prostate cancer in a patient, comprising determining the expression of an androgen regulated gene in a biological sample comprising prostate cells, wherein the androgen-regulated gene is PMEPA1, wherein expression of the PMEPA1 gene is determined by measuring the level of expression of a PMEPA1 nucleotide sequence comprising SEQ ID NO:

2 in the biological sample, and wherein reduced expression of the PMEPA1 gene in the biological sample as compared to a control sample comprising noncancerous prostate cells correlates with an increased probability for advanced prostate cancer, wherein the advanced prostate cancer is characterized by at least pathological T3 disease.

7. The method of claim 6, wherein the advanced prostate cancer comprises non-organ confined tumors, wherein the tumors are not confined to the prostate gland.

8. The method of claim 7, wherein expression of the PMEPA1 gene in the biological sample is reduced at least 1.5 fold as compared to the control sample.

9. The method of claim 7, wherein the level of expression of the PMEPA1 nucleotide sequence is determined after amplifying the PMEPA1 nucleotide sequence in the biological sample.

10. The method of claim 9, wherein the PMEPA1 nucleotide sequence is amplified using a first PCR primer having the nucleotide sequence of SEQ ID NO:

77 and a second PCR primer having the nucleotide sequence of SEQ ID NO;

78.

11. The method of claim 9, wherein the expression of the PMEPA1 nucleotide sequence is detected using a probe having the nucleotide sequence of SEQ ID NO:

79.